ATTR Cardiac Amyloidosis in a Selected Population

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50+
SponsorHelse Møre og Romsdal HF

About this trial

Patients operated for carpal tunnel syndrome (CTS) at Ålesund Hospital (200 patients) will have a biopsy to diagnose ATTR amyloidosis. Patients with positive biopsy will be examined to decide wether they have cardiac amyloidosis. All patients with positive biopsy will be followed closely for 10 years wit echocardiography an clinically.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Male > 50 years

Female > 60 years

operated CTS at Ålesund Hospital

Disqualifiers

not consented

do not speak Norwegian

secondary cause of CTS as traumatic or rheumatic

cannot be followed > 5 years due to other medical conditions

Trial population

Maximum 200 patients operated at Ålesund Hospital for CTS

Trial design

Design model

Case-only

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Frequency of ATTR in CTS

Biopsy proven ATTR

Time frame
2 years
2

Cardiac involvement in patients with biopsy proven ATTR

Scintigraphic and echocardiographic cardiac involvement possibly cMRI

Time frame
10 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.